Emerging Technologies in Pharmaceutical Sciences
From discovery to delivery, the transformation has already begun
Abhishek Rungta, Founder and CEO, INT. (Indus Net Technologies Ltd.)
Pharmaceutical science is changing how drugs are discovered, tested, manufactured, and monitored. This article talks about the growing use of AI, digital twins, and autonomous systems across the pharmaceutical lifecycle, their impact on development timelines and costs, and what their adoption could mean for pharmaceutical companies across Asia in the coming years.
The pharmaceutical industry has always been defined by two constants: the extraordinary complexity of what it does, and the extraordinary cost of doing it. Bringing a single drug from discovery to approval has historically taken 10 to 15 years and cost an average of US$2.6 billion. The attrition rate across that journey sits at 96 per cent, meaning 96 out of all 100 drug candidates fail before they reach a patient. These numbers have been the defining constraint of pharmaceutical science for decades.
They are now being fundamentally challenged by a convergence of emerging technologies that is reshaping every stage of the pharmaceutical value chain simultaneously. This is not incremental progress. It is a structural shift in the economics and architecture of pharmaceutical science, and Asia sits at the centre of it.
Artificial Intelligence in Drug Discovery
The most consequential change in pharmaceutical sciences over the last three years has not happened in a laboratory. It happened in a computer cluster.
As of early 2026, over 173 AI-originated drug programs are in clinical development, up from approximately 24 in late 2023. AI-discovered molecules are demonstrating an 80 to 90 per cent success rate in Phase I trials, compared to the historical average of approximately 52 per cent. McKinsey &Co. estimates that generative AI could save the pharmaceutical industry between US$60 billion and US$110 billion annually across the value chain. In February 2026, Insilico Medicine announced that the first fully AI-designed drug for idiopathic pulmonary fibrosis had completed Phase IIa trials with statistically significant efficacy. The drug was designed and optimised using AI in 18 months at a computational and discovery cost of approximately US$6 million. The traditional path to the same milestone costs US$100 to US$200 million and takes 6 to 8 years.
That is not a marginal improvement in efficiency. It is a cost inversion so dramatic that it forces every player in the industry to reconsider the fundamentals of how drug development is structured and funded. For Asia's pharmaceutical companies, which have historically competed on generics manufacturing rather than originator drug development, AI drug discovery represents the most significant opportunity to move upstream in the pharmaceutical value chain that has ever existed.
Digital Twins Across the Pharmaceutical Lifecycle
Digital twins, virtual replicas of physical systems that are continuously updated through real-world data flows, are proving transformative across three distinct stages of pharmaceutical science.
In drug discovery, protein-ligand digital twins powered by AlphaFold3 are reducing target validation timelines from months to days. In manufacturing, process analytical technology-integrated continuous manufacturing digital twins are improving active pharmaceutical ingredient consistency to 99.95%. In personalised medicine, patient-specific digital twins are predicting optimal dosages within 7% of actual clinical outcomes. Sanofi has launched a company-wide digital twin initiative across its clinical and manufacturing operations, a signal of how seriously the industry's largest players are treating this technology.
For Asian pharmaceutical manufacturers, digital twins offer a particularly powerful application in supply chain resilience. AI-driven predictive analytics and supply chain digital twins enable pharma companies to model demand volatility, regulatory disruptions, and logistics constraints across complex multi-market export networks before those disruptions materialise. In a post-pandemic sector where single-source dependencies have been exposed as a systemic risk, that predictive capability is rapidly moving from competitive advantage to operational necessity.
Agentic AI in Clinical Operations and Pharmacovigilance
Beyond drug discovery, agentic AI, autonomous systems capable of executing multi-step workflows with minimal human intervention, is beginning to transform clinical operations and pharmacovigilance in ways that address some of the sector's most persistent inefficiencies.
In clinical trials, AI is reducing development timelines by 25 per cent and clinical trial costs by up to 70 per cent in documented deployments. Patient recruitment, historically one of the most time-consuming and costly elements of trial management, is being accelerated by AI systems that can identify eligible patients across electronic health records and patient registries at a scale that manual processes cannot match.
In pharmacovigilance, the shift is equally significant. Signal detection, which traditionally occurred on a monthly or quarterly basis through manual review of individual case safety reports, is moving toward real-time continuous monitoring. Agentic AI systems can autonomously handle end-to-end pharmacovigilance workflows, from translating adverse event reports across multiple languages to auto-populating regulatory submissions. Early adopters are reporting up to 40 per cent of pharmacovigilance capacity reclaimed through this automation, with safety professionals redeployed from data entry to complex signal assessment and regulatory judgement. The FDA published draft guidance in 2025 on using AI to support regulatory decision-making for drug and biological products, signalling that the regulatory framework is actively evolving to accommodate these capabilities.
The Integration Imperative
Each of these technologies creates value in isolation. Their compounding potential is unlocked only through integration.
A pharmaceutical company that uses AI for drug discovery but runs its manufacturing on legacy systems, its clinical operations on disconnected platforms, and its pharmacovigilance on manual workflows is capturing a fraction of the value that a fully integrated digital infrastructure could deliver. The companies that will define Asian pharmaceutical science over the next decade are not the ones that deploy the most AI tools. They are the ones that build the data architecture, integration layers, and governance frameworks that allow AI to function reliably and accountably across the entire enterprise.
The AI drug discovery market is estimated at US$4.46 billion in 2025 and is projected to reach US$5 billion by 2026, with an estimated 30 per cent of new drug programmes now incorporating AI at some stage. The technology is no longer experimental. The question for pharmaceutical leaders in Asia is not whether to engage with these technologies, but whether their organisations have the digital infrastructure to deploy them at scale, with the data quality and integration depth that enterprise-grade pharmaceutical AI demands.
The transformation of pharmaceutical sciences is not arriving. It has already begun for the companies that are building the right foundations.
Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.
